華康生物醫學(08622.HK)前三季度收益輕微增加約1.0%至1880萬元
格隆匯11月9日丨華康生物醫學(08622.HK)公吿,截至2022年9月30日止9個月,公司錄得的收益較去年同期輕微增加約1.0%至約人民幣1880萬元。收入增加主要來自於報吿期間集團男性不育體外診斷試劑的銷售增加。
集團的毛利率由去年同期約63.6%增加至報吿期間約67.8%。該增加主要由於銷售健康產品及保健品分部的毛利率有所改善。
報吿期間,期內公司擁有人應占虧損約人民幣555,000元,比較去年同期約人民幣230萬元。減少乃主要有關報吿期間毛利及其他收益增加及行政開支減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.